Idiopathic pulmonary fibrosis (IPF) is the most common progressive interstitial disease of
unknown etiology. The course of the disease cannot be predicted with certainty. It is crucial …

Background: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial
pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first …

In addition to idiopathic pulmonary fibrosis (IPF), other diffuse interstitial lung diseases (ILD)
are also associated with pulmonary fibrosis and occur in a variable proportion of patients …

Pirfenidone and nintedanib are the only two drugs approved for the treatment of idiopathic
pulmonary fibrosis (IPF). Both proved to be safe and well-tolerated in clinical trials, but real …

Background: Nintedanib slows disease progression in patients with Idiopathic Pulmonary
Fibrosis (IPF) by reducing decline in Forced Vital Capacity (FVC). The effects of nintedanib …

Idiopathic pulmonary fibrosis (IPF) remains a challenging disease to manage. Two drugs are
now available that can slow disease progression in patients with mild-to-moderate IPF. This …

Background: Nintedanib has been investigated as a treatment for IPF in three randomized,
placebo-controlled, 52-week trials: the Phase 2 TOMORROW trial and the two replicate …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial pneumonia of unknown
cause, characterised by progressive worsening in lung function and dyspnoea with an …

Objective: To review the pharmacology, safety, and efficacy of nintedanib for the treatment of
idiopathic pulmonary fibrosis (IPF). Methods: A literature search was conducted via PubMed …

Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial
pneumonia and is characterized by a poor prognosis, with an estimated 5-year survival of …